

AD _____

GRANT NUMBER DAMD17-97-1-7321

TITLE: Dominant-Active Alleles of Rb1 as Universal Tumor Suppressors of Mammary Carcinoma

PRINCIPAL INVESTIGATOR: Eldad Zacksenhaus, Ph.D.

CONTRACTING ORGANIZATION: The Toronto Hospital
Toronto, Canada M5G 2C4

REPORT DATE: September 1998

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

*Form Approved
OMB No. 0704-0188*

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY <i>(Leave blank)</i>	2. REPORT DATE September 1998	3. REPORT TYPE AND DATES COVERED Annual (1 Sep 97 - 31 Aug 98)	
4. TITLE AND SUBTITLE Dominant-Active Alleles of Rb1 as Universal Tumor Suppressors of Mammary Carcinoma		5. FUNDING NUMBERS DAMD17-97-1-7321	
6. AUTHOR(S) Eldad Zacksenhaus, Ph.D.			
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)		PAGE	
The Toronto Hospital Toronto, Canada M5G 2C4			
1. AGENCY USE ONLY <i>(Leave blank)</i>	2. REPORT DATE September 1998	3. REPORT TYPE AND DATES COVERED Annual (1 Sep 97 - 31 Aug 98)	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)		10. SPONSORING / MONITORING AGENCY REPORT NUMBER DAMD17-97-1-7321	
4. TITLE AND SUBTITLE U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			
5. AUTHOR(S)			
11. SUPPLEMENTARY NOTES		19990622 048	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)			
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited		12b. DISTRIBUTION CODE DAMD17-97-1-7321	
1. AGENCY USE ONLY <i>(Leave blank)</i>	2. REPORT DATE September 1998	3. REPORT TYPE AND DATES COVERED Annual (1 Sep 97 - 31 Aug 98)	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)		10. SPONSORING / MONITORING AGENCY REPORT NUMBER DAMD17-97-1-7321	
13. ABSTRACT <i>(Maximum 200 words)</i> U.S. Army Medical Research and Materiel Command The tumor suppressor Rb is thought to be genetically or functionally inactivated in virtually all human cancers including, breast cancer. The Rb protein is negatively regulated by cyclin dependent kinases. The goal of this project is to generate transgenic mice expressing phosphorylation-resistant Rb in the mammary gland and test whether these dominant active alleles of Rb can prevent breast cancer induced by distinct oncogenic pathways in mouse models. In the past year, we have constructed the transgenic plasmids and established 23-MMTV-RbΔK transgenic lines. RT-PCR analysis revealed that some of the transgenic lines expressed various levels of the transgene. We are currently testing the expression of the transgenes in the rest of the lines and study the effect of the transgenes on development of the mammary gland. We will next mate the MMTV-RbΔK transgenic mice with MMTV-myc, MMTV-cyclinD1 and MMTV-neu in order to test whether expression of unphosphorylated Rb can suppress breast cancer in mouse models. If our studies indicate that Rb can prevent or reverse neoplastic growth, future studies will focus on designing strategies to activate the Rb pathway as preventive or therapeutic treatments for breast cancer.			
13. ABSTRACT <i>(Maximum 200 words)</i>			
14. SUBJECT TERMS Breast Cancer		15. NUMBER OF PAGES 14	
16. PRICE CODE			
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

PI - Signature

Date

e-Jackson Jr. Sept 28 1998

Table of Content:

p.1. FRONT COVER

p.2. STANDARD FORM (SF) 298

p.3 FOREWORD

P.4 TABLE OF CONTENT

pp.5-14 I. INTRODUCTION

II. BODY

II.1 Mutagenesis of phosphorylation sites in Rb (Fig. 1)

II.2 Construction of MMTV-RbΔK transgenic vectors (Fig. 2)

II.3 Generation of MMTV-RbΔK transgenic mice

II.4 Expression analysis of MMTV-RbΔK transgenic mice

III. CONCLUSIONS

IV. REFERENCES

V. APPENDICES

V.1 Fig. 3

V.II Fig. 4

V.III Fig. 5

I. INTRODUCTION


The tumor suppressor Rb controls cell growth, differentiation and survival for modulating the activities of transcription and differentiation factors (9) (8) (7) (11). Rb is either mutated or functionally inactivated in virtually all human cancer including breast cancer. Functional inactivation of Rb occurs by dysregulation of cyclin-dependent kinases (CDKs) that phosphorylate the protein (6). The goal of this project is to assess the effect of blocking functional inactivation of Rb on the development of breast cancer in mouse models (3). To this end we are targeting phosphorylation-resistant (ΔK) alleles of Rb to the mammary gland of transgenic mice using the mouse mammary tumor virus (MMTV) promoter. MMTV-Rb ΔK transgenic mice will then be mated with other MMTV-onc mice predisposed to breast cancer (1), to test whether unphosphorylated Rb can act as a universal tumor suppressor in the mammary gland.

II. BODY

II.1 Mutagenesis of phosphorylation sites in Rb

Fig. 1 shows a schematic structure of Rb, the consensus Ser/Thr CDK-phosphorylation sites and the sites mutated in Rb ΔK alleles.

Fig. 1: Phosphorylation sites in Rb and Rb ΔK alleles




These Rb constructs contain a Kozak translation initiation consensus sequence followed by an HA epitope. Rb $\Delta p34$ has been kindly provided by Dr. P. Hamel, University of Toronto. In this Rb allele, eight phosphorylation sites have been mutated to Ala rendering it hyperactive (2). Nevertheless, transfection of Rb $\Delta p34$ cannot inhibit Rat1 cell proliferation (4). In contrast, a

chimeric human-mouse Rb protein in which three additional phosphorylation sites are mutated in the COOH-terminus can inhibit Rat1 cell proliferation (4). We created a similar Rb allele, termed Rb Δ K11, by mutating S773, T814, T819, in the Rb Δ p34 backbone. Mutagenesis was accomplished by complex PCR, using Pfu Taq polymerase to reduce the risk of unwanted mutations. Subsequent sequencing of the resulting Rb Δ K11 clones revealed no fortuitous mutations. To ensure that Rb Δ K11 is functionally active, we transfected the pECE-HA-Rb Δ K11 plasmid into COS cells, immunoprecipitated with HA-antibodies and Western blotted with anti-large T antibody, as described (10). We found that Rb Δ K11 could efficiently bind large T (data not shown). In addition, we transfected pECE-HA-Rb Δ K11 and pBabe-puro into Saos-2 cells in which transfected Rb induces cell growth arrest and the formation of giant cells (10). We found that pECE-HA-Rb Δ K11 suppresses growth of Saos-2 cells indicating that the protein is functionally active (data not shown).

We are currently mutating to Ala two additional sites, Thr364 and Thr367, upstream of the A domain of Rb by PCR based mutagenesis to create pECE-Rb Δ K13 (see **Fig. 1**). This will generate an Rb allele with all CDK sites mutated except for S561 in the pocket domain which we chose not to mutate as it may affect biological activity of Rb.

II.2 Construction of MMTV-Rb Δ K transgenic vectors

Rb Δ p34 and Rb Δ K11 were subcloned into a MMTV expression vector, kindly provided by Dr. R. Coffey (5). The MMTV backbone was subcloned as a XhoI fragment into pBluscript which we modified to contain a unique XhoI site flanked by NotI sites. This allows subsequent excision of the MMTV-Rb Δ K alleles by NotI digest prior to pronuclear injection. This step was necessary because as opposed to wild-type Rb, Rb Δ p34 and Rb Δ K11 contain a XhoI site in their coding sequence. The MMTV-Rb Δ p34 and -Rb Δ K11 plasmids are depicted in **Fig. 2**.

Fig. 2. Structure of MMTV-RbΔp34 and -ΔK11 transgenes

To verify that the Rb alleles are correctly expressed and that the MMTV-promoter is hormonally induced, the MMTV-RbΔK plasmids were transfected into COS cells together with a plasmid expressing the glucocorticoid receptor. Transfected cells were treated with dexamethasone (Dex) for 24 hrs. Dex treated cultures expressed the Rb alleles as was revealed by immunostaining and IP/Western blots. Control cultures that did not receive Dex, did not express Rb (data not shown).

II.3 Generation of MMTV-RbΔK transgenic mice

The MMTV-RbΔp34 and -RbΔK11 plasmids were digested with NotI to release the transgene from the vector DNA, and purified from gels using a Geneclean extraction kit followed by Elutip column. The purified DNA was micro-injected into fertilized nuclei at the Transgenic Mouse Facilities at the Hospital for Sick Children and The Ontario Cancer Institutes. We routinely check the DNA from the first litter by Southern blot hybridization (e.g. Fig. 3); all subsequent genotyping has been done by PCR analysis using primers for Rb (exon 23) and β-globin exon-2 (not shown).

So far, we generated 16 MMTV-RbΔp34 and 7 MMTV-RbΔK11 transgenic founders and obtained successful germ line transmission for all of them. The MMTV-RbΔp34 mice were created and analyzed first. These mice are on a mixed background and are currently crossed into FvB background. The MMTV-RbΔK11 mice are already on a pure FvB background.

II.4 Expression analysis of MMTV-RbΔK transgenic mice

To assess the level of expression of the Rb transgenes, MMTV-RbΔp34 females were sacrificed at different developmental stages and total RNA was extracted from mammary glands #4 with the Trizol reagent (Gibco BRL). The RNA was either (a) purified on a poly-dT column

(Qiagen) for Northern blots or (b) re-extracted with Trizol to minimize contaminating DNA and used for RT-PCR. **Fig. 4** shows a Northern blot of RNA isolated from MMTV-Rb Δ p34 clone #24 virgin female. A 4.6 kb band corresponding to endogenous Rb as well as a weaker 3.6 kb fragment corresponding to the transgene are observed. RNA from a non-transgenic control mouse did not express the 3.6 kb band. Since MMTV transgenes are expressed exclusively in the mammary epithelium whereas Rb is expressed in other breast tissues, including adipocytes (our unpublished *in situ* hybridization data), the level of the transgene relative to endogenous Rb in the mammary epithelium is higher than appears from the blot.

We subsequently optimized conditions to detect Rb transgene transcripts by RT-PCR. Lines #27 and #30 express the transgene, whereas two other lines do not (**Fig. 5** and data not shown). This simplified RT-PCR approach is currently being used to screen all F1 transgenic lines for expression of the Rb transgene at different developmental stages of the mammary gland. Lines expressing highest levels of the transgenes will be further analyzed for expression by Northern Blots, IP/Western blots and immuno-histochemistry with anti-HA antibodies. The effect of ectopic expression of unphosphorylatable Rb will then be analyzed by whole mount hematoxilin staining and cross sections at different stages of mammary gland development. The ability of the MMTV-Rb Δ p34 and -Rb Δ K11 transgenic females to lactate will also be determined. This gross analysis will be accompanied by additional molecular analysis such as BrdU incorporation and PCNA staining to assess proliferation index, and marker analysis depending on the phenotype of the transgenic mice. Highly expressing MMTV-Rb Δ p34 and -Rb Δ K11 transgenic mice will be genetically crossed with MMTV-onc mice as outlined in the proposal.

III. CONCLUSIONS

In the past year, we have made the expected progress in our project. We have constructed transgenic plasmids expressing unphosphorylatable Rb and verified that the Rb Δ K alleles are functionally active. We made constructs in which increasing numbers of Ser/Thr CDK sites in Rb were mutated so we can assess whether partial or complete protection of Rb from phosphorylation is required *in vivo* to block breast cancer. Studies by others revealed the necessity to screen

multiple MMTV transgenic founders to obtain mice with specific, uniform and inducible expression of the transgene. In addition, MMTV transgenic mice were reported to express very low levels of the transgene which is often amplified in tumors (1). We therefore generated a large collection of transgenic MMTV-RbΔK mice and are carefully monitoring their expression levels. The work we accomplished in this first year of grant support and our current analysis will form the basis for the genetic studies. We will mate the MMTV-RbΔK transgenic mice with MMTV-cyclin D1, -myc and -neu, which are often amplified in human cancer and test whether dominant active alleles of Rb can protect from breast cancer initiated by these distinct oncogenes. This analysis will allow us to determine *in vivo* whether inactivation of Rb is an obligatory step in the progression of breast cancer and whether therapeutic approaches directed at activation of the Rb pathway should be attempted for the treatment or prevention of breast cancer.

IV. REFERENCES

1. Callahan, R. 1996. MMTV-induced mutations in mouse mammary tumors: Their potential relevance to human breast cancer. *Breast Cancer Res. & Treat.* 39:33-44.
2. Hamel, P. A., R. M. Gill, R. A. Phillips, and B. L. Gallie. 1992. Transcriptional repression of the E2-containing promoters EIIaE, *c-myc* and *RBI* by the product of the *RBI* gene. *Mol. Cell. Biol.* 12:3431-3438.
3. Hennighausen, L., and G. W. Robinson. 1998. Think globally, act locally: the making of a mouse mammary gland. *Genes Dev* 12:449-455.
4. Knudsen, E. S., and J. Y. Wang. 1997. Dual mechanisms for the inhibition of E2F binding to RB by cyclin-dependent kinase-mediated RB phosphorylation. *Mol Cell Biol* 17:5771-5783.
5. Matsui, Y., S. A. Halter, J. T. Holt, B. L. M. Hogan, and R. J. Coffey. 1990. Development of mammary hyperplasia and neoplasia in MMTV-TGF α transgenic mice. *Cell* 61:1147-1155.
6. Mitnacht, S. 1998. Control of pRB phosphorylation. *Curr Opin Genet Dev* 8:21-27.

7. Mulligan, G., and T. Jacks. 1998. The retinoblastoma gene family: cousins with overlapping interests. *Trends Genet* 14:223-229.
8. Weinberg, R. A. 1995. The retinoblastoma protein and the cell cycle. *Cell* 81:323-330.
9. Zacksenhaus, E., R. Bremner, Z. Jiang, R. M. Gill, M. Muncaster, M. Sopta, R. A. Phillips, and B. L. Gallie. 1993. Unraveling the function of the retinoblastoma gene. *Adv. Cancer Res.* 61:115-141.
10. Zacksenhaus, E., R. Bremner, R. A. Phillips, and B. L. Gallie. 1993. A bipartite nuclear localization signal in the retinoblastoma gene product and its importance for biological activity. *Mol. Cell. Biol.* 13:4588-4599.
11. Zacksenhaus, E., Z. Jiang, D. Chung, J. Marth, R. A. Phillips, and B. L. Gallie. 1996. pRb controls cell proliferation, differentiation and death of skeletal muscle cells and other lineages during embryogenesis. *Genes & Dev* 10:3051-3064.

V. APPENDICES

Fig. 3 Southern blot analysis of DNA isolated from first litter following micro-injection of MMTV- Δ p34. The DNA was digested with SacI, Southern blotted and hybridized with a probe that spans the MMTV vector DNA. The original vector, also digested with SacI, was used as a positive control.

Fig. 4. Northern blot analysis on 2 ug of polyadenylated RNA extracted from whole mammary glands of transgenic MMTV- Δ p34 clone #24 and control littermate. Endogenous and transgenic Rb species are indicated. Note that expression of transgenic Rb is from mammary epithelial cells whereas endogenous Rb is expressed in different mammary gland cell types.

Fig. 5. RT-PCR analysis of MMTV- Δ p34 . Two and three independent mice from lines #27 and #30 are shown, respectively. RT, reverse transcriptase.

Plasmid control

MMTV-RbΔK tail DNA

1 2 3 4 5




Fig. 3





Fig. 4

MMTV- Δ p34**Fig. 5**